Table 1.
Completion of the three PRO instruments at each assessment during the study
| Week | mSICT | Palatability | GI Symptom Diary* | |||
|---|---|---|---|---|---|---|
| Deferasirox DT N = 86 n (%) |
Deferasirox FCT N = 87 n (%) |
Deferasirox DT N = 86 n (%) |
Deferasirox FCT N = 87 n (%) |
Deferasirox DT N = 86 n (%) |
Deferasirox FCT N = 87 n (%) |
|
| −2 | 60 (69.8) | 59 (67.8) | ||||
| −1 | 62 (72.1) | 52 (59.8) | ||||
| 1 | 70 (81.4) | 69 (79.3) | ||||
| 2 | 70 (81.4) | 70 (80.5) | 69 (80.2) | 70 (80.5) | 65 (75.6) | 71 (81.6) |
| 3 | 58 (67.4) | 51 (58.6) | 57 (66.3) | 51 (58.6) | 64 (74.4) | 66 (75.9) |
| 4 | 60 (69.8) | 64 (73.6) | ||||
| 5 | 58 (67.4) | 64 (73.6) | ||||
| 6 | 64 (74.4) | 57 (65.5) | ||||
| 7 | 57 (66.3) | 53 (60.9) | ||||
| 8 | 59 (68.6) | 51 (58.6) | ||||
| 9 | 55 (64.0) | 49 (56.3) | ||||
| 10 | 53 (61.6) | 49 (56.3) | ||||
| 11 | 51 (59.3) | 44 (50.6) | ||||
| 12 | 51 (59.3) | 45 (51.7) | ||||
| 13 | 59 (68.6) | 64 (73.6) | 59 (68.6) | 62 (71.3) | 49 (57.0) | 50 (57.5) |
| 14 | 51 (59.3) | 44 (50.6) | ||||
| 15 | 49 (57.0) | 43 (49.4) | ||||
| 16 | 48 (55.8) | 41 (47.1) | ||||
| 17 | 44 (51.2) | 40 (46.0) | ||||
| 18 | 44 (51.2) | 38 (43.7) | ||||
| 19 | 40 (46.5) | 37 (42.5) | ||||
| 20 | 40 (46.5) | 39 (44.8) | ||||
| 21 | 39 (45.3) | 37 (42.5) | ||||
| 22 | 38 (44.2) | 35 (40.2) | ||||
| 23 | 36 (41.9) | 34 (39.1) | ||||
| 24 | 63 (73.3) | 60 (69.0) | 63 (73.3) | 60 (69.0) | 32 (37.2) | 26 (29.9) |
SOT for the mSICT and palatability were defined as the first PRO assessment at week 2 (or week 3 if missing); for the GI Symptom Diary, week 1 was taken as SOT; *includes patients with at least four complete daily responses. DT Dispersible tablet, FCT Film-coated tablet, GI Gastrointestinal, PRO Patient-reported outcome, mSICT modified Satisfaction with iron chelation therapy, SOT Start of treatment